Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-21T06:36:46.507Z Has data issue: false hasContentIssue false

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus

Published online by Cambridge University Press:  11 June 2019

Rights & Permissions [Opens in a new window]

Abstract

Type
Corrigendum
Copyright
© Cambridge University Press 2019 

In the original publication “Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus,” by Black et al. (Reference Black, Nasrallah and Isaacson2018), the authors regret the errors found in Table 1; Boxes 1, 3, and 4; and Figure 1. The correct Table 1, Boxes 1, 3, and 4, and Figure 1 are given below.

Table 1 Receptor binding affinities for select antipsychotic agents

+ weak binding affinity (100>Ki<1000)

++ moderate binding affinity (10>Ki<100)

+++ strong binding affinity (1>Ki<10)

++++ very strong binding affinity (Ki<1)

Abbreviations: 5-HT = serotonin; α = adrenergic; D = dopamine; H = histamine; M = muscarinic.

Ki (nM) values are derived from functional antagonist R-SATTM assays (ACADIA, San Diego, CA, USA).

“-” denotes no response.

Adapted from Hacksell et. al. Neurochem Res 2014; 39:2008-2017 and from data on file.

Box 1. Dosing tips for switching to pimavanserin from low-dose (≤ 100 mg) Quetiapine (see Figure 3)

  • Add full dose (34 mg) pimavanserin to current low dose (up to 100 mg) quetiapine for 4 weeks

  • Allows pimavanserin to reach steady state and the duration of treatment necessary to reach its delayed onset of therapeutic action

  • Then reduce quetiapine by 50% weekly until reaching 12.5 mg, then discontinue

  • If efficacy for PDP diminishes during quetiapine taper, can return to previous dose level and try tapering again in 1 week

Box 3. Dosing tips for switching to pimavanserin from low-dose (≤ 100 mg) Clozapine (see Figure 5)

  • Add full dose (34 mg) pimavanserin to continuing clozapine dose for 6 weeks

  • Then reduce clozapine by 6.25 mg weekly until discontinued and in no event, not less than 4 weeks of tapering

  • If efficacy for PDP diminishes during clozapine taper, can return to previous dose level and try tapering again in 1 week

  • Recommend not removing patient from clozapine registry for a few months in case clozapine must be restarted

Box 4. Dosing tips for switching to pimavanserin from high-dose (> 100 mg) Clozapine (see Figure 6)

  • Add full dose (34 mg) pimavanserin to continuing clozapine dose for 6 weeks

  • Then reduce clozapine by 25 mg weekly until discontinued and in no event, not less than 4 weeks of tapering

  • If efficacy for PDP diminishes during clozapine taper, can return to previous dose level and try tapering again in 1 week

  • Recommend not removing patient from clozapine registry for a few months in case clozapine must be restarted

Figure 1 Patients not currently taking antipsychotic medication. Start full dose of Pimavanserin immediately.

In addition, the authors would like to make the following text corrections and clarifications:

Page 405:

  • The MDS EBM was published in 2011.

Page 406:

  • The doses in the early phase 2b/3 study were placebo, 8.5, and 34 mg/d.

  • The P-value for the hallucination and delusions subscales was 0.0012.

  • Sleep quality, caregiver burden, etc. were exploratory outcomes.

Page 407:

  • The QT prolongation for pimavanserin is 5-8 msec.

The original publication has been corrected to reflect these changes.

References

Black, K, Nasrallah, H, Isaacson, S, et al. (2018). Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: An expert consensus. CNS Spectrums. 2018; 23(6):402413. doi:10.1017/S1092852918001359CrossRefGoogle Scholar
Figure 0

Table 1 Receptor binding affinities for select antipsychotic agents

Figure 1

Figure 1 Patients not currently taking antipsychotic medication. Start full dose of Pimavanserin immediately.